Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis

The understanding of the impact of the non-canonical NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway in several human diseases including autoimmune, inflammatory and cancers has been on the rise. This pathway induces the expression of several important genes involved in diverse biological processes. Though progress has been made in understanding the activation, regulation and biological functions of the non-canonical NF-kappa B signaling mechanism, no specific drug has been approved to target NF-kappa B inducing kinase (NIK), the key signaling molecule in this pathway. The inhibition of NIK can serve as a potential therapeutic strategy for various ailments, especially for the treatment of different types of human cancers. There are other targetable downstream molecules in this pathway as well. This review highlights the possible role of the non-canonical NF-kappa B pathway in normal physiology as well as in different cancers and discusses about various pharmacological strategies to modulate the activation of this pathway.